Manufacturing Therapeutic Exosomes: from Bench to Industry
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Process of manufacturing therapeutics exosome development for commercialization. The development of exosome treatment starts at the bench, and in order to be commercialized, it goes through the manufacturing, characterization, and formulation stages, production under Good Manufacturing Practice (GMP) conditions for clinical use, and close consultation with regulatory authorities. Exosome, a type of nanoparticles also known as small extracellular vesicles are gaining attention as novel therapeutics for various diseases because of their ability to deliver genetic or bioactive molecules to recipient cells. Although many pharmaceutical companies are gradually developing exosome therapeutics, numerous hurdles remain regarding manufacture of clinical-grade exosomes for therapeutic use. In this mini-review, we will discuss the manufacturing challenges of therapeutic exosomes, including cell line development, upstream cell culture, and downstream purification process. In addition, developing proper formulations for exosome storage and, establishing good manufacturing practice facility for producing therapeutic exosomes remains as challenges for developing clinicalgrade exosomes. However, owing to the lack of consensus regarding the guidelines for manufacturing therapeutic exosomes, close communication between regulators and companies is required for the successful development of exosome therapeutics. This review shares the challenges and perspectives regarding the manufacture and quality control of clinical grade exosomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“Standardized protocols or guidance for exosome quality attributes are needed regardless of the originator cell line type and culture conditions (Doyle and Wang, 2019; Thery et al., 2018).”
BackgroundMethodSelf-citationExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“EVs are lipid vesicles secreted by almost all cell types and are categorized based on their biological properties and biogenesis pathways (Raposo and Stoorvogel, 2013; Thery et al., 2018; 2002).”
BackgroundEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 2×
“harvest conditions, separation and purification methods, and stability (Théry et al., 2006; Zhang et al., 2020b).”
BackgroundMethodPegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682 · cited 1×
“They are generally termed lipid vesicles and are generated by inward invagination from endosomes (Pegtel and Gould, 2019).”
BackgroundZhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s264498 · Cited by 1,323
Webber, J., & Clayton, A. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.19861 · Cited by 817 · cited 1×
“In previous research, exosome purity was assessed by measuring the total particle number of exosomes per total protein (pn/μg) or by measuring the amount of proteins of a specific size (Huang and He, 2017; Webber and Clayton, 2013).”
MethodYim, N., Ryu, S.-W., Choi, K., Lee, K. R., Lee, S., Choi, H., Kim, J., Shaker, M. R., Sun, W., Park, J.-H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12277 · Cited by 578 · cited 2×
“In addition to stem cells and immune cells, the HEK293 cell line, which is commonly used for the production of therapeutic proteins, has also been used to produce exosomes for therapeutic use (Malm et al., 2020; Song et al., 2021; Yim et al., 2016).”
BackgroundSelf-citationCao, J., Wang, B., Tang, T., Lv, L., Ding, Z., Li, Z., Hu, R., Wei, Q., Shen, A., Fu, Y., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01719-2 · Cited by 264 · cited 1×
“In practice, adherent-type two-dimensional and suspension-type three-dimensional cultures in both single-use culture systems are used to produce stable exosomes at a 1,000-2,000 L industrial scale (Cao et al., 2020; Thippabhotla et al., 2019).”
MethodRationale and design of the Kidney Precision Medicine Project
de Boer, I. H., Alpers, C. E., Azeloglu, E. U., Balis, U. G. J., Barasch, J. M., Barisoni, L., Blank, K. N., Bomback, A. S., Brown, K., Dagher, P. C., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.039 · Cited by 187
Cited by
Verma, N., & Arora, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080990 · Cited by 173
Exosomes: a promising avenue for cancer diagnosis beyond treatment
Wang, Z., Wang, Q., Qin, F., & Chen, J. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1344705 · Cited by 66
Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01906-1 · Cited by 48
Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy
Chen, Y., Tang, S., Cai, F., & Wan, Y. (2024) · Research · doi:10.34133/research.0421 · Cited by 26
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Uti, D. E., Egbung, J. E., Anthony, B. O., Omari, O. R., Omang, W. A., Aggad, W. S., Almohaimeed, H. M., Bainsal, N., Shukla, S. K., Ealla, K. K. R., et al. (2026) · Discover Nano · doi:10.1186/s11671-026-04681-9 · Cited by 3
Metadata
- Authors
- Ahn, S.-H., Ryu, S.-W., Choi, H., You, S., Park, J., & Choi, C.
- Venue
- Molecules and Cells
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 45
- Issue
- 5
- Pages
- 284-290
- ISSN
- 0219-1032 (ISSN-L)
- 1016-8478
- OpenAlex
- W4229448444
- Cited by
- 191
- References
- 10
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.